← All trials
NCT04447846
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 14, 2019
- Primary completion
- Feb 28, 2021
- Completion date
- Apr 30, 2021
- First posted
- Jun 25, 2020
- Last posted
- Jun 25, 2020
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.Lead sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.Sponsor investigator
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.Overall official - principal investigator
- GW Pharmaceuticals Ltd.Collaborator
- Faneca 66 FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.